March 28 (Reuters) - Vertex Pharmaceuticals Inc
said on Tuesday its Kalydeco cystic fibrosis treatment given
with an experimental drug demonstrated significant improvements
in lung function in a pair of late-stage trials the company
plans to use to seek approval for the combination therapy.
Read more
No comments:
Post a Comment